The private placement corresponds to 1 446 280 new shares.
The number of shares after the issue is now 28 121 566 and the company’s share capital after the issue is 3 374 587.92. For further information about the issue, see press release on November 1st, 2017.
For more information, please contact:
Jan Alenfall – VD, Follicum AB
Telephone: 046 -19 21 97
About Follicum AB
Follicum is a biotech company focused on the discovery and development of peptide-based drugs. The primary focus is in hair growth stimulation, where Follicum has obtained very promising results with FOL-005 in a recently completed clinical trial. In diabetes, the drug candidate FOL-014 has demonstrated an increase in insulin release in pre-clinical models. The company was founded in 2011, and is based in Lund, Sweden. Follicum is listed on the Swedish small cap exchange Aktietorget since 2014. www.follicum.com